Zobrazeno 1 - 10
of 5 023
pro vyhledávání: ''
Publikováno v:
Recent Patents on Anti-Cancer Drug Discovery. 17:268-283
Background: The ubiquitin-proteasome system (UPS) is critical in cellular protein degradation and widely involved in the regulations of cancer hallmarks. Targeting the UPS pathway has emerged as a promising novel treatment in hematological malignanci
Autor:
Hekun Liu, Jie Lin, Zichan Dai, Binghui Zhang, Rangxin Peng, Tae Ho Lee, Qi Han, Kun Ping Lu, Min Zheng, Xiaohan Wang, Mingting Jiang, Jichuang Wang, Junjin Lin
Publikováno v:
Cancer Letters. 524:161-171
Sorafenib and its derivative regorafenib are the first- and second-line targeted drugs for advanced HCC, respectively. Although both drugs improve overall survival, drug resistance remains the major barrier to their full efficacy. Thus, strategies to
Autor:
Diana Abbott, Clayton A. Smith, Julie Rosser, Mohd Minhajuddin, Maria L. Amaya, Jeffrey Schowinsky, Daniel A. Pollyea, Anagha Inguva, Craig T. Jordan, Amanda Winters, Christine McMahon, Jonathan A. Gutman, Audrey Sato, Evan Cherry, Marc Schwartz, Shanshan Pei, Brett M. Stevens
Publikováno v:
Blood Advances
Key Points Patients with AML who received IC were compared with those who received ven to investigate predictors of outcomes.Presence of RUNX1 mutations is associated with better outcomes for ven/aza compared with IC.
Visual Abstract
Veneto
Visual Abstract
Veneto
Autor:
Iraklis Mitsogiannis, Anna Boulouta, Dionysios Mitropoulos, Charalampos Fragkoulis, Nikolaos Ferakis, Ioannis Adamakis, Nikos Dedes, Charalambos Deliveliotis, Andreas Skolarikos, Konstantinos Ntoumas, Constantinos Constantinides, Athanasios Papatsoris, Konstantinos Stravodimos, Stamatina Pagoni, Ioannis Anastasiou, Roubini Zakopoulou, Aristotelis Bamias, Meletios A. Dimopoulos, Konstantinos Koutsoukos, Kimon Tzannis, Nikos G. Gavalas, Eythymios Kostouros, Athanasios Dellis
Publikováno v:
Current Oncology, Vol 28, Iss 380, Pp 4474-4484 (2021)
Current Oncology
Volume 28
Issue 6
Pages 380-4484
Current Oncology
Volume 28
Issue 6
Pages 380-4484
We previously showed that ERCC1 19007 C>
T polymorphism was associated with cancer-specific survival (CSS) after platinum-based chemotherapy in patients with advanced urothelial cancer (aUC). We aimed to confirm this association in a different
T polymorphism was associated with cancer-specific survival (CSS) after platinum-based chemotherapy in patients with advanced urothelial cancer (aUC). We aimed to confirm this association in a different
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-8 (2021)
BMC Cancer
BMC cancer, Vol. 21, no. 1, p. 1204 (2021)
BMC cancer, Vol. 21, no. 1, p. 1204 [1-8] (2021)
BMC Cancer
BMC cancer, Vol. 21, no. 1, p. 1204 (2021)
BMC cancer, Vol. 21, no. 1, p. 1204 [1-8] (2021)
Background Trastuzumab emtansine (T-DM1) is indicated as second-line treatment for human epidermal growth factor receptor 2 (HER2)-positive metastatic or unresectable locally advanced breast cancer, after progression on trastuzumab and a taxane-based
Autor:
Laura van 't Veer, Laura J. Esserman, Øystein Garred, Olav Engebraaten, Maria E B Berstad, Christina Yau, Elin Borgen, Anette Weyergang, Ane Sofie Viset Fremstedal, Angela DeMichele, Kristian Berg
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
Nature Communications
Nature communications, vol 12, iss 1
Nature Communications
Nature communications, vol 12, iss 1
HER2 is a predictive biomarker for HER2-targeted therapeutics. For antibody–drug conjugates (ADCs; e.g., trastuzumab emtansine (T-DM1)), HER2 is utilized as a transport gate for cytotoxic agents into the cell. ADC biomarkers may therefore be more c
Autor:
Denise M. Wolf, Jane Perlmutter, Judy C. Boughey, A. Jo Chien, Meredith Buxton, Gillian L. Hirst, Douglas Yee, Angela DeMichele, Andres Forero-Torres, Scott M. Berry, Erin D. Ellis, Anthony D. Elias, Julia Wulfkuhle, Michael Alvarado, Christina Yau, Stacy L. Moulder, Nola M. Hylton, Rita Nanda, Amy Wilson, Adam Asare, Debu Tripathy, Claudine Isaacs, Melissa Paoloni, Rosa I. Gallagher, Laura J. Esserman, Richard Schwab, W. Fraser Symmans, Cheryl Ewing, Laura J. van't Veer, Jeffrey B. Matthews, Teresa Helsten, Julia L. Clennell, Barbara Haley, Emanuel F. Petricoin, Katherine Steeg, Smita Asare, Ashish Sanil, Rachel L. Yung, Erin P. Crane, Erin Roesch, Hyo S. Han, Ruby Singhrao, Michelle E. Melisko, Hope S. Rugo, Kathy S. Albain, Donald A. Berry, Anne M. Wallace, Julie E. Lang, Amy S. Clark, Kathleen Kemmer, Lamorna Brown-Swigart
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
Nature communications, vol 12, iss 1
Nature Communications
Nature communications, vol 12, iss 1
Nature Communications
HER2-targeted therapy dramatically improves outcomes in early breast cancer. Here we report the results of two HER2-targeted combinations in the neoadjuvant I-SPY2 phase 2 adaptive platform trial for early breast cancer at high risk of recurrence: ad
Publikováno v:
Anticancer Research. 41:5729-5737
Background/aim This study aimed to identify the predictive markers for carboplatin-induced severe thrombocytopenia. Patients and methods We conducted a retrospective cohort analysis of inpatients who received carboplatin and pemetrexed. Results Among
Publikováno v:
Cancer Biol Ther
Biguanide drugs (metformin and phenformin) have drawn interest for potential cancer treatments, and laboratory studies show that some cancer cells are selectively sensitive to growth-inhibitory effects of biguanides. Examining metabolic pathways affe
Autor:
Nancy Chan, Jiuping Ji, Antoinette R. Tan, Janice M. Mehnert, Alice P. Chen, Jan H. Beumer, Mansi Shah, Joseph Aisner, Murugesan Gounder, Jyoti Malhotra, Rebecca A. Moss, Yong Lin, Brian F. Kiesel, Hongxia Lin, Mark N. Stein, Michael P. Kane
Publikováno v:
Cancer Chemother Pharmacol
Purpose Veliparib (V), an oral poly(ADP-ribose) polymerase (PARP) inhibitor, potentiates effects of alkylating agents and topoisomerase inhibitors in preclinical tumor models. We conducted a phase I trial of V with iv cyclophosphamide (C) and V plus